Venture
ADARx Pharmaceuticals, Inc.
Latest Form D 2023-08-10- CIK 1802369
- State CA
- Biotechnology
- 7 Form D offerings since 2020-02-06
- Total sold
- $353M
- across 7 offerings
- Rounds
- 7
- Form D offerings since 2020-02-06
- Latest round
- $200M
- 2023-08-10 · 021-489353
- Investors
- 28
- on the latest round
Connected
named in its Form D filingsOfferings · since 2020-02-067 Form D offeringsExemptions506(b)People · Item 3Zhen Li + 10 moreInvestors · dashboardInferred investors
ADARx Pharmaceuticals, Inc.CIK 1802369
Round timeline
amount sold · by first filed2023-08-10 · $200M
- 2020-02-06$5M021-359900
- 2020-08-07$5M021-372735
- 2020-11-17$6M021-380734
- 2021-05-24$15.5M021-400299
- 2021-08-17$75M021-410307
- 2023-01-26$46M021-471878
- 2023-08-10$200M021-489353
Hover a dot or row, or tab through the dots · bars scaled to the largest round ($200M)
Form D offerings
One line per offering, amendments folded in, newest first
| File | First filed | Latest | Sought | Sold | Investors | Exemptions |
|---|---|---|---|---|---|---|
| 021-489353 | First filed2023-08-10 | Latest2023-08-10 | Sought$200M | Sold$200M | Investors28 | Exemptions506(b) |
| 021-471878 | First filed2023-01-26 | Latest2023-01-26 | Sought$46M | Sold$46M | Investors10 | Exemptions506(b) |
| 021-410307 | First filed2021-08-17 | Latest2021-08-17 | Sought$75M | Sold$75M | Investors6 | Exemptions506(b) |
| 021-400299 | First filed2021-05-24 | Latest2021-05-24 | Sought$15.5M | Sold$15.5M | Investors3 | Exemptions506(b) |
| 021-380734 | First filed2020-11-17 | Latest2020-11-17 | Sought$6M | Sold$6M | Investors3 | Exemptions506(b) |
| 021-372735 | First filed2020-08-07 | Latest2020-08-07 | Sought$5M | Sold$5M | Investors3 | Exemptions506(b) |
| 021-359900 | First filed2020-02-06 | Latest2020-02-06 | Sought$5M | Sold$5M | Investors3 | Exemptions506(b) |
Who backs ADARx Pharmaceuticals, Inc., inferred from co-filings, and every Form D as filedSee plans
People
Named in Item 3 of its latest Form D, filed 2023-08-10
| Name | Relationship |
|---|---|
| Zhen Li | RelationshipExecutive Officer, Director, Promoter |
| Rui Zhu | RelationshipExecutive Officer |
| Lorence Kim | RelationshipDirector |
| Simeon George | RelationshipDirector |
| Yuan (Eliza) Sun | RelationshipDirector |
| Erez Chimovits | RelationshipDirector |
| Carl Gordon | RelationshipDirector |
| Judith Li | RelationshipDirector |
| Sheila Gujrathi | RelationshipDirector |
| Ricky Sun | RelationshipDirector |
| Chen Yu | RelationshipDirector |
Facts
As its latest Form D states them
- Industry
- Biotechnology
- State
- California (CA)
- Exemptions
- Rule 506(b)
- First filed
- 2020-02-06
- Latest filing
- 2023-08-10
Who backs ADARx Pharmaceuticals, Inc.
Form D names a startup's officers and directors, not its investors. The dashboard infers them — the venture funds whose own filings and people overlap this company's rounds — and lays every Form D and amendment it filed beside the totals above.
- Inferred investors — the funds and firms behind it, from co-filings and shared people
- Every Form D and amendment as filed, with what each one stated
- Its rounds in sequence: the gap between them and whether they grew
- Everyone its filings name, linked to their other companies, with its addresses and phone numbers
Part of the Venture plan — $140/mo at launch pricing ($350 list)
See plansExternal link: SEC Filings ↗